Armis Biopharma
BiotechnologyColorado, United States2-10 Employees
Armis Biopharma, Inc. is a Fort Collins, Colorado-based biotechnology research company focused on developing non-systemic anti-infective therapies aimed at countering antibiotic resistance and healthcare-associated infections. The organization maintains a growing pipeline of targeted antimicrobial treatments intended for use in healthcare settings to reduce infection-related harm. Its mission centers on decreasing the incidence and severity of infections that cause human suffering and death through new antimicrobial modalities. The lead technology, Veriox, relies on a novel mechanism of action designed to be effective against a broad range of pathogens, including Gram-positive and Gram-negative bacteria, viruses, fungi, spores, and chemical/biological warfare pathogens, while aiming to minimize systemic toxicity. The company’s target customers are healthcare providers and institutions seeking therapies that mitigate resistant infections and related complications. In July 2024, Armis Biopharma appointed Michael Voss as chief executive officer, succeeding Ted Ziemann, who retired after six years at the helm.
1-888-653-2347 
support@leadiq.com 
